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The evidence in support of drug eluting stents (DES) in the
coronary vasculature is presently more robust than that in the
infrapopliteal arteries.Much of the data describing peripheral use is
limited to small single center series with short-term follow-up. It is
apparent that direct translation of the coronary experience to the
infrapopliteal arteries is problematic and vascular surgeons, and our
cardiology colleagues, should be reminded that coronary lesions
are not tibial lesions, and vice versa.
The PADI Study is one of several (including SIROCCO)
multicenter randomized studies that might clarify the roleof DES in peripheral arteries. However, neointimal hyper-
plasia is an ongoing process and it is uncertain whether the
limited duration of drug delivery offered by DES will alter
restenosis rates beyond the 1-year duration of this study’s
follow-up.
Regardless, the results of such a study could offer an important
contribution to our understanding of the role of this technology.
Until such randomized multicenter data is available, however,
there is little data supporting the widespread use of DES in the
infrapopliteal arteries.
